Controversial psychologist and author Jordan Peterson claimed Western countries had no “moral right” to force developing nations to reduce pollution output, noting instead that improving their economies was key.
During an appearance on the BBC’s ‘Question Time’ show on Thursday, the Canadian professor noted that the focus of climate change policies should be on incentivizing the development of cheap energy in poorer polluter countries.
“The best long term solution is to try to make developing countries as rich as possible, and the best way to do that is not control their pollution output, but to help them develop the cheapest energy they can possibly manage as fast as they possibly can,” Peterson said.
The debate saw UK undersecretary for employment Mims Davies suggest that measures taken to tackle climate change should not come at the “expense of developing countries.” But Peterson countered that it “absolutely, 100% will be [at their expense].”
I don’t think we have any moral right in the West at all to do that.
He also criticized the recent COP26 climate change conference for failing to explore ideas on how best to improve national economies in the developing world, noting that he saw “very little of that sort of idea” coming out of the UN summit.
In the final hours of the two-week conference, China and India had intervened to soften the wording around the use of coal in the Glasgow Pact. The two countries demanded a change in the final text of the agreement that called for coal to be phased out, revising this to “phasing down unabated coal.”
The move prompted COP26 president and UK minister Alok Sharma to declare that China and India would have to “justify” their actions to countries that were more vulnerable to global warming effects. However, officials in both Beijing and New Delhi have countered that the criticism was unfair.
AstraZeneca has announced that its preventative antibody cocktail offers 83% protection against symptomatic Covid-19 for at least six months, making it more effective than its own vaccine.
In a statement on Thursday, AstraZeneca cemented its lead in the race to develop and market a preventative Covid-19 drug, which is delivered as a shot in the arm.
The drug, named AZD7442, reduces the risk of symptomatic Covid-19 by 83% over the course of six months, according to data from a trial in which participants were given one 300mg dose. There were no deaths or severe infections recorded within the trial group, it said.
A separate trial showed the drug reduced the risk of severe Covid-19 or death by 88% when administered within three days of the onset of symptoms.
“These new data add to the growing body of evidence supporting AZD7442’s potential … We are progressing regulatory filings around the world and look forward to providing an important new option against SARS-CoV-2 [Covid-19] as quickly as possible,” AstraZeneca Executive Vice President Mene Pangalos said in the statement.
The Anglo-Swedish firm has agreed to supply the US government with 700,000 doses of AZD7442 if the Food and Drug Administration grants it emergency use, which AstraZeneca requested on October 5. The firm has similar agreements with other nations.
The drug is created using a combination of two antibodies originating from immune B-cells donated by a recovering Covid-19 patient.
The treatment could be used in people who are known not to respond well to vaccines, such as cancer patients. Around 2% of people are considered to be at risk of not creating enough antibodies following the administration of a Covid-19 vaccine.
Based on the numbers, the drug appears to be more effective than the firm’s first-generation Covid-19 vaccine. Britain’s Zoe Covid study showed the effectiveness of the vaccine dropped to around 67% after four to five months.
